Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab maintenance after second-line chemoradiotherapy for locally or regionally recurrent esophageal squamous cell carcinoma
ChiCTR1900027161Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoints: Treatment-related adverse events and Initial tumor response. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900027161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027161.